The Promise of a CMV Vaccine

A single-antigen CMV vaccine provided substantial protection for postpartum women.

Congenital cytomegalovirus (CMV) infection is an important cause of neurological (particularly auditory) impairment in newborns, and the Institute of Medicine has ranked development of a vaccine to prevent congenital CMV infection as a top priority. Women who care for young children (primarily infants and toddlers) have higher risk for CMV acquisition than those who do not. In a manufacturer-supported phase II study of CMV glycoprotein B vaccine with MF59 adjuvant, investigators randomized 464 CMV-seronegative postpartum women to receive three doses of vaccine (at baseline, 1 month, and 6 months) or placebo within 1 year after delivery. Participants were followed for ≤42 months. CMV acquisition was determined with viral culture, polymerase …

Reviewing Author

Anna Wald, MD, MPH

Disclosures

Consultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)

RoyaltiesUpToDate

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris

Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases

Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)